Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars

Follows Backing To Be Listed On The Quebec Public Health Plan

Executive Summary

Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.

You may also be interested in...



Valeo Pharma To Launch Enoxaparin In Canada Early Next Year

Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.

Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences

Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.

Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia

Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel